Journal
FRONTIERS IN PHARMACOLOGY
Volume 9, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2018.01425
Keywords
FKBP ligands; FKBP12; FKBP51; AIPL1; MIP; Rapamycin; FK506; SAFit
Categories
Funding
- M4 Award 2015 from the StMWIVT [BIO-1601-0003]
- BMBF/ERA-IB grant TACRODRUGS [031B0269B]
- German Research Foundation
- Open Access Publishing Fund of Technische Universitat Darmstadt
Ask authors/readers for more resources
In recent years, many members of the FK506-binding protein (FKBP) family were increasingly linked to various diseases. The binding domain of FKBPs differs only in a few amino acid residues, but their biological roles are versatile. High-affinity ligands with selectivity between close homologs are scarce. This review will give an overview of the most prominent ligands developed for FKBPs and highlight a perspective for future developments. More precisely, human FKBPs and correlated diseases will be discussed as well as microbial FKBPs in the context of anti-bacterial and anti-fungal therapeutics. The last section gives insights into high-affinity ligands as chemical tools and dimerizers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available